Previous 10 | Next 10 |
GBS (NASDAQ:GBS) is trading 10% higher before the bell after it announced on Thursday an exclusive agreement to acquire UK-based drug screening firm Intelligent Fingerprinting (IFP). Under the agreement, GBS has the exclusive right until December 31, to evaluate and negotiate ...
NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has executed an exclusivity agreement with Intellig...
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS&...
GBS Inc. (GBS) Q3 2022 Earnings Conference Call May 10, 2022, 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Presentation Operator Greetings. And welcome to the GBS In...
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, GBS’s 2022 Annual Meeting of Shareholders w...
GBS press release (NASDAQ:GBS): FQ3 GAAP EPS of -$0.09. Revenue of $192.5M. Shares -2.62% AH. For further details see: GBS GAAP EPS of -$0.09, revenue of $192.5M
- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval - - Finalizing site selection at the University of Newcastle campus for the high-tech manufacturing and production facility - - $10.76 Million in Cash, Cash Equ...
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the third...
GBS (GBS) may issue up to $100M amount of common stock, preferred stock, debt securities, warrants or units of securities consisting of some or all of these securities. Company may sell these securities directly, through underwriters, dealers or agents, or through a combination of these metho...
Gainers: Advent Technologies (ADN) +79%. Tufin Software Technologies (TUFN) +43%. Mobiquity Technologies (OTCQB:MOBQ) +30%. Missfresh (MF) +25%. Venator Materials (VNTR) +17%. Team (TISI) +16%. Concord Medical Services (CCM) +15%. NextDecade (NEXT) +15%. Smart Sand (SND) +13%. ...
News, Short Squeeze, Breakout and More Instantly...
GBS Inc. Company Name:
GBS Stock Symbol:
NASDAQ Market:
The transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reach GBS’ global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (G...
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the ...
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the four...